Want to see SVA full AI Analyst Report?
Sinovac Biotech (SVA) Stock Statistics & Valuation Metrics
Total Valuation
Sinovac Biotech has a market cap or net worth of $460.27M. The enterprise value is $429.15M.
- Market Cap
- $460.27M
- Enterprise Value
- $429.15M
Share Statistics
Sinovac Biotech has 71,860,700 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 71,860,700
- Owned by Insiders
- ―
- Owned by Institutions
- 0.48%
Financial Efficiency
Sinovac Biotech’s return on equity (ROE) is -0.01 and return on invested capital (ROIC) is -3.02%.
- Return on Equity (ROE)
- -0.01
- Return on Assets (ROA)
- -0.01
- Return on Invested Capital (ROIC)
- -3.02%
- Return on Capital Employed (ROCE)
- -0.04
- Revenue Per Employee
- 197.05K
- Profits Per Employee
- -30.46K
- Employee Count
- 1,959
- Asset Turnover
- 0.04
- Inventory Turnover
- 1.32
Valuation Ratios
The current PE Ratio of Sinovac Biotech is -7.80. Sinovac Biotech’s PEG ratio is -0.08.
- PE Ratio
- -7.80
- PS Ratio
- 1.20
- PB Ratio
- 0.10
- Price to FCF
- -0.83
- Price to Operating Cash Flow
- -0.91
- PEG Ratio
- -0.08
Income Statement
In the last 12 months, Sinovac Biotech had revenue of 386.01M and earned -59.68M in profits. Earnings per share was -0.83.
- Revenue
- 386.01M
- Gross Profit
- 261.98M
- Operating Income
- -291.32M
- Pretax Income
- -262.10M
- Net Income
- -59.68M
- EBITDA
- -187.66M
- Earnings Per Share (EPS)
- -0.83
Cash Flow
In the last 12 months, operating cash flow was 106.02M and capital expenditures -145.69M, giving a free cash flow of -39.67M billion.
- Operating Cash Flow
- 106.02M
- Free Cash Flow
- -39.67M
- Free Cash Flow per Share
- -7.78
Dividends & Yields
Sinovac Biotech pays an annual dividend of $55.00, resulting in a dividend yield of ―
- Dividend Per Share
- $55.00
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -120.32%
- Earnings Yield
- -12.84%
Stock Price Statistics
- Beta
- ―
- 52-Week Price Change
- 0.00%
- 50-Day Moving Average
- 6.47
- 200-Day Moving Average
- 6.47
- Relative Strength Index (RSI)
- ―
- Average Volume (3m)
- 8,227
Important Dates
Sinovac Biotech upcoming earnings date is May 03, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Aug 17, 2026
- Next Earnings Date
- May 03, 2027
- Ex-Dividend Date
- Jul 08, 2025
Financial Position
Sinovac Biotech as a current ratio of 4.59, with Debt / Equity ratio of 11.42%
- Current Ratio
- 4.59
- Quick Ratio
- 4.53
- Debt to Market Cap
- 1.07
- Net Debt to EBITDA
- 3.46
- Interest Coverage Ratio
- -29.67
Taxes
In the past 12 months, Sinovac Biotech has paid -63.27M in taxes.
- Income Tax
- -63.27M
- Effective Tax Rate
- 0.24
Enterprise Valuation
Sinovac Biotech EV to EBITDA ratio is 0.98, with an EV/FCF ratio of 0.33.
- EV to Sales
- -0.48
- EV to EBITDA
- 0.98
- EV to Free Cash Flow
- 0.33
- EV to Operating Cash Flow
- 0.36
Balance Sheet
Sinovac Biotech has $11.22B in cash and marketable securities with $298.98M in debt, giving a net cash position of $10.92B billion.
- Cash & Marketable Securities
- $11.22B
- Total Debt
- $298.98M
- Net Cash
- $10.92B
- Net Cash Per Share
- $152.02
- Tangible Book Value Per Share
- $119.96
Margins
Gross margin is 67.87%, with operating margin of -75.47%, and net profit margin of -15.46%.
- Gross Margin
- 67.87%
- Operating Margin
- -75.47%
- Pretax Margin
- -67.90%
- Net Profit Margin
- -15.46%
- EBITDA Margin
- -48.61%
- EBIT Margin
- -75.47%
Analyst Forecast
The average price target for Sinovac Biotech is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- 8.78%
- EPS Growth Forecast
- -227.47%
Scores
- Smart Score
- 5
- AI Score
- 49
